title: Evaluation of current and upcoming therapies in oral mucositis prevention.
abstract: Cancer chemotherapy has evolved from a few therapeutic agents in three drug classes to more than 50 drugs in over ten drug classes. With generally cytotoxic mechanisms of action, there is continued research interest in preventing and managing adverse events of chemotherapy. Although treatment-induced symptom management has made significant progress, most therapies lead to intolerable reactions that result in a dose reduction or discontinuation of therapy. Mucositis is a common adverse event that can occur after administration of systemic chemotherapy and/or radiation therapy leading to inflammatory lesions anywhere from the oral cavity to the GI tract. Although pathophysiologically similar, gastrointestinal mucositis and oral mucositis (OM) differ in terms of symptom presentation and offending therapies. The focus of the article will be on OM; gastrointestinal mucositis will be mentioned when therapy efficacy is relevant to OM. OM prophylaxis has been a subject of interest for at least the past 30 years, yet progress has been limited due to a lack of understanding of the condition. With the recent introduction of palifermin (Kepivance™), novel therapies continue to be developed that may significantly reduce the incidence, duration and/or severity of OM. In addition, outcomes including an improvement in patient quality of life, increasing treatment dose intensity or reducing healthcare costs may result from successful management of OM prophylaxis. This article will review currently available OM prophylactic therapies. Agents in preclinical or clinical development and natural supplements will also be discussed.
authors.affiliation: Skaggs School of Pharmacy & Pharmaceutical Sciences University of California, San Diego 9500 Gilman Drive, MC 0714, San Diego, CA 92093, USA.
authors.forename: Jerry C
authors.initials: JC
authors.lastname: Wu
authors.forename: Keola K
authors.initials: KK
authors.lastname: Beale
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Ma
mesh_terms: D019587:Dietary Supplements; D006801:Humans; D012720:Severity of Illness Index; D013280:Stomatitis / Q000473:pathology / Q000517:prevention & control* / Q000628:therapy*; D035703:Therapies, Investigational / Q000592:standards / Q000639:trends